Compare EVC & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EVC | ACHV |
|---|---|---|
| Founded | 1996 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Broadcasting | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 335.0M | 172.0M |
| IPO Year | 2000 | 2018 |
| Metric | EVC | ACHV |
|---|---|---|
| Price | $9.66 | $4.69 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $14.67 |
| AVG Volume (30 Days) | ★ 4.0M | 1.2M |
| Earning Date | 05-05-2026 | 05-11-2026 |
| Dividend Yield | ★ 5.35% | N/A |
| EPS Growth | ★ 47.59 | N/A |
| EPS | ★ 0.13 | N/A |
| Revenue | ★ $536,034,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $73.85 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.90 | $2.00 |
| 52 Week High | $9.60 | $6.15 |
| Indicator | EVC | ACHV |
|---|---|---|
| Relative Strength Index (RSI) | 76.24 | 50.17 |
| Support Level | $2.66 | $4.65 |
| Resistance Level | N/A | $4.98 |
| Average True Range (ATR) | 1.01 | 0.42 |
| MACD | 0.17 | -0.11 |
| Stochastic Oscillator | 92.64 | 20.16 |
Entravision Communications Corp owns and operates Spanish language television and radio stations in the United States. The Company also owns and operates a smaller group of television stations that broadcast English language programming and has operations that provide programmatic advertising technology and services. The Company has organized its operations into two reportable segments. Its media segment includes its television, radio, and digital marketing operations. Its advertising and technology services segment provides programmatic advertising and technology services. The company generates the majority of its revenue from the advertising and technology services segment. Geographically, the company generates the majority of its revenue from the United States.
Achieve Life Sciences Inc is a late-stage clinical specialty pharmaceutical company with the sole mission to address the nicotine dependence epidemic through the development and commercialization of cytisinicline. Cytisinicline, is a naturally occurring alkaloid. Additionally, The company has completed a Phase 2 study with cytisinicline in vaping cessation and conducted a successful end-of-Phase 2 meeting with the FDA for a future vaping indication. It operates in one operating segment, development and commercialization of cytisinicline for nicotine dependence, with operations located in Canada, the United States and the U.K.